Amgen Inc. ( AMGN) Q4 2025 Earnings Call February 3, 2026 4:30 PM EST ...
Investor's Business Daily on MSN
Amgen hits buy zone on positive 2026 outlook amid sharpening obesity focus
Amgen is running a number of studies of its obesity drug, MariTide.
Amgen (NASDAQ:AMGN) executives highlighted broad-based growth in 2025 and laid out expectations for continued momentum in ...
Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but it has expanded its portfolio to include innovative drugs in therapeutic areas ranging from ...
Amgen Inc. delivered strong operational performance across the board in 2025, and you can see that in the breadth of our business. Three of these, Repatha, Evenity, and TestSpire, all grew by more ...
Short- and long-acting bronchodilators are inhaled medications that can be used separately or in combination to manage COPD.
Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results